[Breast feeding of infants with phenylketonuria]

F Hinrichs1, B Biggemann, U Wendel

  • 1Kinderklinik, Heinrich-Heine-Universität, Düsseldort.

Insights

Breastfeeding is safe for infants with phenylketonuria (PKU). This study found no significant differences in weight gain or phenylalanine levels between breastfed infants and those receiving formula, supporting continued breastfeeding for PKU management.

Area of Science:

  • Pediatrics
  • Metabolic Disorders
  • Human Nutrition

Background:

  • Phenylketonuria (PKU) is a genetic disorder requiring careful dietary management of phenylalanine intake.
  • Breast milk is a natural source of phenylalanine, posing challenges for PKU infant feeding.
  • Infant formula provides a controlled phenylalanine source, but breastfeeding offers numerous benefits.

Purpose of the Study:

  • To compare the outcomes of breastfeeding versus infant formula feeding in infants with phenylketonuria.
  • To assess the impact of different phenylalanine sources on infant growth and metabolic control in PKU.

Main Methods:

  • A comparative study involving two groups of five infants diagnosed with phenylketonuria.
  • Group 1 received breast milk as the primary phenylalanine source.
  • Group 2 received standard infant formula as the primary phenylalanine source.

Main Results:

  • No statistically significant differences were observed in weight gain between the two groups.
  • Daily phenylalanine intake and mean plasma phenylalanine concentrations were comparable across both groups.
  • Breastfeeding did not negatively impact metabolic control or growth in infants with PKU.

Conclusions:

  • Breastfeeding can be safely continued for infants diagnosed with phenylketonuria.
  • Dietary management of PKU can accommodate phenylalanine from breast milk, despite variable intake.
  • This finding supports breastfeeding as a viable option for managing phenylketonuria in infants.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Taste During Infancy01:20

Taste During Infancy

The sense of taste begins developing before birth and is shaped by biological predispositions and early experience. During pregnancy, flavors from foods consumed by the mother can enter the amniotic fluid, exposing the fetus to different flavors. These prenatal experiences may contribute to food preferences after birth.Prenatal and Breastfeeding InfluencesAfter birth, flavors from a mother’s diet can also pass into breast milk. Repeated exposure to these flavors during breastfeeding may make...